KalVista Pharmaceuticals, Inc. $KALV Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. decreased its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 8.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 276,000 shares of the specialty pharmaceutical company's stock after selling 24,000 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 0.56% of KalVista Pharmaceuticals worth $3,185,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Rhumbline Advisers boosted its position in shares of KalVista Pharmaceuticals by 3.4% in the 1st quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock worth $611,000 after purchasing an additional 1,762 shares in the last quarter. Corebridge Financial Inc. lifted its position in KalVista Pharmaceuticals by 12.7% during the 1st quarter. Corebridge Financial Inc. now owns 19,094 shares of the specialty pharmaceutical company's stock worth $220,000 after acquiring an additional 2,149 shares during the period. MetLife Investment Management LLC lifted its position in KalVista Pharmaceuticals by 13.2% during the 1st quarter. MetLife Investment Management LLC now owns 21,688 shares of the specialty pharmaceutical company's stock worth $250,000 after acquiring an additional 2,536 shares during the period. Wellington Management Group LLP lifted its position in KalVista Pharmaceuticals by 2.8% during the 1st quarter. Wellington Management Group LLP now owns 126,268 shares of the specialty pharmaceutical company's stock worth $1,457,000 after acquiring an additional 3,405 shares during the period. Finally, GAMMA Investing LLC lifted its position in KalVista Pharmaceuticals by 567.3% during the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock worth $51,000 after acquiring an additional 3,767 shares during the period.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,942 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the sale, the insider directly owned 119,841 shares in the company, valued at approximately $1,584,298.02. The trade was a 2.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the company's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the transaction, the chief executive officer owned 369,595 shares of the company's stock, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,835 shares of company stock valued at $892,350. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Leerink Partners boosted their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, July 7th. JMP Securities upped their price target on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 8th. Finally, HC Wainwright upped their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $26.29.

KalVista Pharmaceuticals Stock Down 3.1%

KALV traded down $0.48 during midday trading on Thursday, hitting $14.91. The company had a trading volume of 2,274,013 shares, compared to its average volume of 801,298. The stock's 50 day moving average price is $14.04 and its 200 day moving average price is $12.74. The company has a market capitalization of $750.52 million, a price-to-earnings ratio of -4.06 and a beta of -0.10. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.21). The company had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.97 million. Research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).